The Efficacy of Intracranial Thrombectomy for Acute Ischemic Stroke in Posterior Circulation Stroke Center, Ise Red-Cross Hospital

Masaru Seguchi, Masunari Shibata, Hideki Nakajima, Kota Maekawa, Yotaro Kitano, Akane Mizutani, Takanori Sano, . Kobayashi Kazuto, Masayoshi Yamasaki, Hiroshi Tanemura、Genshin Mouri, Yutaka Naito, Fumitaka Miya

BACKGROOUND / PURPOSE

- Despite recent breakthroughs in the treatment of ischemic stroke, patients with posterior circulation (PC) occlusion were excluded from randomized controlled trials.
- The AHA/ASA guidelines state that there is uncertainty about the benefit of thrombectomy in basilar artery occlusion (BAO).
- We investigated the outcome of acute phase mechanical thrombectomy (MT) involving PC.

MFTHOD

- We performed a retrospective analysis of all patients who underwent MT for acute ischemic stroke involving PC at our institution from January 2011 to May 2017.
- MT was indicated for patients who were transferred within 24 hours after onset, without an extensive irreversible impairment in the brain stem.
- We evaluated the clinical outcome using modified Rankin scale (mRS) at 90 days. Patients with a mRS score of 0 to 3 were regarded as achieving a 'favorable outcome', and those with an mRS score of 4 to 6 as showing a 'poor outcome'.

Patients c	haracteristics and outcome	n = 26		Favorable	Poor outcome						
Background	Age, mean (SD)	76.2 ± 10.1		outcome	(mRS 4-6)	P-value	m	nodified Rankin Scale			
	Male, n (%)	13 (50.0)		n = 6	n = 20						
	pre-NIHSS ^{*1} score, mean (SD)	26.2 ± 8.1	Age, median (quartile)	78.5 (68.3 - 79.8)	81.0 (74.0 - 84.0)	N.S.	■ 0	1 2	3 4	5 6	
Occlusion vessel	Basilar artery, n (%)	23 (88.5)	Male, n (%)	4 (66.7)	9 (45.0)	N.S.					
	Vertebral artery, n (%)	3 (11.5)	Pre-operativel NIHSS ^{*1} , mean (SD)	18.5 (11.0 - 26.8)	29.0 (24.5 - 33.0)	0.03	At discharge	1212	7	11	2
Subtype	CE ^{*2} , n (%)	16 (61.5)	PC-ASPECTS ^{*2} , median (quartile)	8 (6 - 8.5)	7 (7 - 8.5)	N.S.	At 90 days				
	ATBI ^{*3} , n (%)	5 (19.2)	Basilar artery occlusion, n (%)	4 (66.7)	19 (95.0)	N.S.					
	Other. n (%)	5 (19.2)	Vertebral artery occlusion, n (%)	1 (16.7)	2 (10.0)	N.S.		1 2 1 2	7	0	4
	Cr. maan (CD)	0.8 + 0.2	PCA ^{*3} occlusion, n (%)	1 (16.7)	0 (0.0)	N.S.		1 2 1 2	/	9	4
Laboratory data	Cr, mean (SD)	0.8 ± 0.2	Cardiogenic embolization, n (%)	4 (66.7)	12 (60.0)	N.S.					
	HbA1c (NGSP), mean (SD)	6.8 ± 1.8	ATBI ^{*4} , n (%)	0 (0.0)	5 (25.0)	N.S.					
Time-course	O2D ^{*4} , median (quartile)	360 (170 - 765)	Other type, n (%)	2 (33.3)	3 (15.0)	N.S.		Present	Singer	Mokin	Espino
	D2P ^{*5} median (quartile)	104 (56 - 139)	eGFR, median (quartile)	75.5 (62.8 - 79.3)	68.5 (57.3 - 87.5)	N.S.		study	et al.	et al.	sa et al.
	P2R ^{*6} , median (quartile)	52 (34 - 86)	HbA1c (NGSP), median (quartile)	6.2 (6.1 - 6.5)	6.7 (5.7 - 8.0)	N.S.	Case number	26	148	100	18
Treatment	IV-tPA	5 (19.2)	O2D ^{*5} , median (quartile)	500.5 (153.5 - 831.5)	360.0 (170.0 - 703.0)	N.S.	(II) Age (vr)	76	71	64	69
	Stent-retriever, n (%)	11 (42.3)	DDD*6 medien (mertile)	76.0 (60.5. 414.0)	107.0 (53.0 -	NG	NIHSS	76	/1	04	00
	Penumbra, n (%)	20 (76.9)	D2P *, median (quartile)	76.0 (60.5 - 114.0)	138.5)	N.S.		26	20	19	20
	IA-Urokinase, n (%)	7 (26.9)	P2R ^{*7} , median (quartile)	46.5 (34.5 - 78.0)	52.0 (32.8 - 87.8)	N.S.	Onset-to- Puncture (min)	360	na	562	366
		A (45 A)	Stent-retriever, n (%)	5 (83.3)	6 (30.0)	0.054					
	werci, n (%)	4 (15.4)	Penumbra, n (%)	5 (83.3)	15 (75.0)	N.S.					
Reperfusion status	TICI* ⁷ 2B, n (%)	9 (34.6)	IA-urokinase, n (%)	1 (16.7)	6 (30.0)	N.S.	TICI 2B-3 (%)	92	79	80	94
	TICI 3, n (%)	15 (57.7)	Merci, n (%)	0 (0.0)	4 (20.0)	N.S.					• ·
Clinical outcome	24hr NIHSS score, mean (SD)	16.6 ± 10.6	IV-tPA, n (%)	1 (16.7)	4 (20.0)	N.S.	Favorable outcome (%)	23 mRS 0-3	42 mRS 0-3	35 mRS 0-2	50 mRS 0- 2
	mRS ^{*8} 0-3 at discharge, n (%)	6 (23.1)	NIHSS ar 24br median	6 (100.0)	18 (90.0)	N.S.					
	mPS 0-3 at 90 days n (%)	6 (22.1)	(quartile) NIHSS at discahtge, median	3.5 (1.5 - 4.8) 1.0 (0.0 - 1.0)	21.0 (13.0 - 25.0)	0.03	Mortality (%)	15	35	30	22
	Death at 00 days, II (70)	0 (25.1)									
	Death at 90 days, h (%)	4 (15.4)	(quartile)								
*1: NIH Stroke Scale Score, #2: Cardiogenic cerebral embolism, #3: Atherothrombosis, *4: Onset-to-door time, *5: Door-to-puncture time, *6: Duriture-to-reperfusion time, *7: Thrombolysis in Cerebral Infarction, #8: Modified rankin scale score *1: NIH Stroke Scale Score, #2: posterior circulation alberta stroke *1: NIH Stroke Scale Score, *3: posterior circulation alberta stroke program early CT Score, *3: posterior circulation alberta stroke program early CT Score, *3: posterior corebral artery, *4 Atherothrombosis, *5: One-to-puncture time, *7: Puncture-to-reperfusion time, *8: Thrombolysis in Cerebral Infarction						The Author have no financial conflicts of interest to disclose.					

SUMMERY OF THE RESULTS

- A total of 26 patients including 23 BAO and 3 vertebral artery occlusion were enrolled during the study period. •
- Successfully recanalization was achieved in 24 patients (92.3%). Although 4 patients (15.4%) died, six of 26 patients (23.1%) were favorable outcome at 90 days.
- Compared to poor outcome group, the patients in favorable outcome group were significantly lower preoperative NIHSS (18.5 vs 29.0, P = 0.03) and NIHSS at 24 hours (3.5 vs 21.0, P = 0.03).

DISCUSSION

- Acute BAO has been associated with a high case fatality rate and morbidity. (Fatality rates 20 70%)
- MT involving PC may alleviate the mortality even though among the elderly patients with severe symptom.
 - Harts et al. Lancet Neurol, 2014
- Time to the start procedure is an important predictor of clinical success after thrombectomy in patients with PC strokes. Maxim et al. Stroke. 2016
- The most important patient-related factors determining clinical outcome are initial stroke severity and collateral status. Singer et al. Ann Neurol, 2015
- Scoring systems (BATMAN score, PC-ASPECTS score) were reported as a useful marker for predicting clinical outcome

Alemseged et al. Stroke, 2017 Tei et al. J Neurol, 2010

CONCLUSION

- MT may contribute reduction of the mortality and relief of symptom among the patients with acute vertebrobasilar occlusion.
- Further studies were required to establish the efficacy of MT for patients with PC occlusion.